Drug Profile
Research programme: botulinum immune globulin - Emergent BioSolutions
Alternative Names: BIG; Botulinum immunoglobulinLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Emergent BioSolutions; Health Protection Agency Porton Down
- Developer Emergent BioSolutions
- Class Antibacterials; Antitoxins; Immunoglobulins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Botulism
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Botulism in USA (IV)
- 15 Apr 2008 Preclinical development is ongoing
- 04 Sep 2006 Preclinical trials in Botulism in USA (IV)